Tesofensine for weight loss: what the trials actually found
Quick answer
Tesofensine is an investigational triple monoamine reuptake inhibitor (serotonin, noradrenaline, dopamine) with promising phase 2 weight loss data, particularly from Astrup et al. (2008, The Lancet), but it remains unapproved by the FDA for any indication. The creator's claims about depression improvement and neuroprotection go beyond what current published clinical evidence demonstrates. Patients considering tesofensine through compounding channels should be aware of its cardiovascular side effect profile and the absence of large-scale, long-term safety data.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @myfitmed actually say?
Jay Patel from MyFitMed described tesofensine as a "skinny happy pill" that doubles as a mood booster, calling it "the perfect oral peptide for improving your mood, losing belly fat and improving your overall metabolism." He said it was originally developed for Alzheimer's and Parkinson's disease, works as a serotonin, noradrenaline, and dopamine reuptake inhibitor, and that studies show significant improvements in appetite, satiety, body composition, depression symptoms, insulin sensitivity, and neuroprotection. He also called it an "oral peptide," which is a specific and consequential classification worth examining closely.
The core pitch here is straightforward: tesofensine is a neurologically active weight loss compound with antidepressant-adjacent effects. That framing is not entirely wrong, but it glosses over a lot of inconvenient details, including the compound's regulatory status, its side effect profile, and the actual state of the clinical evidence.
Does the science back this up?
Partially. The weight loss data is actually pretty compelling, but the mental health claims are significantly overstated, and the "oral peptide" label is just scientifically incorrect.
The most-cited tesofensine trial is Astrup et al. (2008, The Lancet), a randomized controlled trial of 203 obese patients over 24 weeks. Participants on 0.5 mg/day lost an average of 12.8 kg, compared to 2.2 kg on placebo. That is genuinely impressive for an oral compound. A follow-up analysis by Sjödin et al. (2010, International Journal of Obesity) confirmed reductions in visceral fat specifically, so the belly fat claim has some grounding.
On mood and depression: the clinical picture is murkier. The triple reuptake mechanism does resemble antidepressants pharmacologically. But calling tesofensine a proven mood-improver or claiming it "improves the symptoms of depression" as a demonstrated benefit overstates what the evidence actually shows. No large, controlled depression-outcome trials have been published. The Alzheimer's development history is accurate (NeuroSearch originally developed it for neurodegeneration), but the neuroprotection claim in otherwise healthy people is speculative at best.
What did they get wrong (or right)?
The biggest factual error is calling tesofensine an "oral peptide." It is not a peptide. Peptides are chains of amino acids. Tesofensine is a small-molecule monoamine reuptake inhibitor, structurally similar to compounds like sibutramine, which was pulled from the US market in 2010 due to cardiovascular risks (James et al., 2010, New England Journal of Medicine). Calling it a peptide is either a misunderstanding of pharmacology or a marketing framing designed to make it sound safer and more natural than it is.
What he got right: the mechanism (triple reuptake inhibition) is accurately described. The original neurological development context is correct. The weight loss magnitude from the Astrup trial is real. The visceral fat reduction finding is supported by data.
What he got wrong or omitted: tesofensine is not FDA-approved for any indication. It is not approved in the US. The side effects, including elevated heart rate, dry mouth, insomnia, and nausea, are absent from this video entirely. The cardiovascular signal that tanked sibutramine is directly relevant here and was not mentioned. The mood and depression benefits are presented as established when they are not.
What should you actually know?
Tesofensine is a real compound with real weight loss data behind it, but the regulatory and safety picture is not what this video implies. It is not FDA-approved. It is available through some compounding pharmacies in the US, but that comes with the standard caveats: compounded medications are not evaluated by the FDA for safety or efficacy, and quality can vary significantly between compounders.
The cardiovascular concern is the one that deserves more airtime than it got here, which is zero. Sibutramine, a similarly acting dual reuptake inhibitor, was removed from the US market after the SCOUT trial showed increased rates of nonfatal heart attack and stroke in high-risk patients (James et al., 2010, NEJM). Tesofensine has a similar mechanism and has shown increases in heart rate in clinical trials. Anyone with hypertension, arrhythmia, or existing cardiovascular risk should ask very specific questions before considering this compound.
The "skinny happy pill" framing is doing a lot of work here. Weight loss medications are medical interventions with real risk profiles. Presenting tesofensine as a mood-enhancing metabolism optimizer without mentioning its unapproved status, its cardiovascular signal, or the limits of the mental health evidence is not balanced health information.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Tesofensine for weight loss: what the trials actually found, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Supports SELECT-context pages where semaglutide claims touch long-term weight change and cardiovascular-risk populations.
PubMed
Semaglutide for cardiovascular event reduction in people with overweight or obesity
Baseline SELECT source for cardiovascular-outcomes framing in people with overweight or obesity.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Tesofensine for weight loss: what the trials actually found is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
Tesofensine is an investigational triple monoamine reuptake inhibitor (serotonin, noradrenaline, dopamine) with promising phase 2 weight loss data, particularly from Astrup et al.
FormBlends verdict
Tesofensine is an investigational triple monoamine reuptake inhibitor (serotonin, noradrenaline, dopamine) with promising phase 2 weight loss data, particularly from Astrup et al. (2008, The Lancet), but it remains unapproved by the FDA for any indication. The creator's claims about depression improvement and neuroprotection go beyond what current published clinical evidence demonstrates. Patients considering tesofensine through compounding channels should be aware of its cardiovascular side effect profile and the absence of large-scale, long-term safety data.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Tesofensine is an investigational triple monoamine reuptake inhibitor (serotonin, noradrenaline, dopamine) with promising phase 2 weight loss data, particularly from Astrup et al. (2008, The Lancet), but it remains unapproved by the FDA for any indication. The creator's claims about depression improvement and neuroprotection go beyond what current published clinical evidence demonstrates. Patients considering tesofensine through compounding channels should be aware of its cardiovascular side effect profile and the absence of large-scale, long-term safety data.
- Tesofensine is not FDA-approved for weight loss, depression, or any other indication in the United States as of 2024.
- The Astrup et al. (2008, The Lancet) phase 2 RCT showed an average 12.8 kg weight loss at 0.5 mg over 24 weeks, which is among the stronger results for an oral agent in this class.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Tesofensine is not FDA-approved for weight loss, depression, or any other indication in the United States as of 2024.
- The Astrup et al. (2008, The Lancet) phase 2 RCT showed an average 12.8 kg weight loss at 0.5 mg over 24 weeks, which is among the stronger results for an oral agent in this class.
- Tesofensine is a small-molecule drug, not a peptide. Calling it an 'oral peptide' is pharmacologically incorrect and may be misleading to consumers.
- Sibutramine, a similar dual reuptake inhibitor, was withdrawn from the US market in 2010 after the SCOUT trial (James et al., NEJM) linked it to increased cardiovascular events. Tesofensine shares a mechanistic profile and has shown heart rate increases in trials.
- No large controlled trial has established tesofensine as an effective antidepressant. The mood-improvement claims in this video are based on mechanism inference, not clinical outcome data.
- Tesofensine is available through some US compounding pharmacies, but compounded preparations are not FDA-evaluated for safety, efficacy, or quality consistency.
- Side effects documented in clinical trials include elevated heart rate, dry mouth, insomnia, and nausea. None of these were mentioned in the video.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
MyFitMed · TikTok creator
9.1K views on this video
Get to know tesofensine #fyp #foryou #myfitmed #health #wellness #brain #brainhealth #medicaltiktok #weightloss #fatloss #foryoupage
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by MyFitMed, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.